dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Peralta-Garcia, Alejandro |
dc.contributor.author | Torrens-Fontanals, Mariona |
dc.contributor.author | Stepniewski, Tomasz Maciej |
dc.contributor.author | Grau Exposito, Judit |
dc.contributor.author | Perea Pérez, David |
dc.contributor.author | Ayinampudi, Vikram |
dc.contributor.author | Buzón Gómez, María José |
dc.contributor.author | Genesca Ferrer, Meritxell |
dc.date.accessioned | 2022-06-15T11:45:19Z |
dc.date.available | 2022-06-15T11:45:19Z |
dc.date.issued | 2021-12 |
dc.identifier.citation | Peralta-Garcia A, Torrens-Fontanals M, Stepniewski TM, Grau-Expósito J, Perea D, Ayinampudi V, et al. Entrectinib—A SARS-CoV-2 Inhibitor in Human Lung Tissue (HLT) Cells. Int J Mol Sci. 2021 Dec;22(24):13592. |
dc.identifier.issn | 1422-0067 |
dc.identifier.uri | https://hdl.handle.net/11351/7684 |
dc.description | COVID-19; Drug repurposing; Viral cell entry assays |
dc.description.abstract | Since the start of the COVID-19 outbreak, pharmaceutical companies and research groups have focused on the development of vaccines and antiviral drugs against SARS-CoV-2. Here, we apply a drug repurposing strategy to identify drug candidates that are able to block the entrance of the virus into human cells. By combining virtual screening with in vitro pseudovirus assays and antiviral assays in Human Lung Tissue (HLT) cells, we identify entrectinib as a potential antiviral drug. |
dc.language.iso | eng |
dc.publisher | MDPI |
dc.relation.ispartofseries | International Journal of Molecular Sciences;22(24) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Medicaments antivírics |
dc.subject | COVID-19 (Malaltia) |
dc.subject | Medicaments - Ús |
dc.subject.mesh | Antiviral Agents |
dc.subject.mesh | /pharmacology |
dc.subject.mesh | Drug Repositioning |
dc.subject.mesh | Coronavirus Infections |
dc.title | Entrectinib—A SARS-CoV-2 Inhibitor in Human Lung Tissue (HLT) Cells |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.3390/ijms222413592 |
dc.subject.decs | antivíricos |
dc.subject.decs | /farmacología |
dc.subject.decs | nuevas indicaciones de medicamentos |
dc.subject.decs | infecciones por Coronavirus |
dc.relation.publishversion | https://doi.org/10.3390/ijms222413592 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Peralta-Garcia A, Torrens-Fontanals M] Research Programme on Biomedical Informatics (GRIB), Department of Experimental and Health Sciences, Hospital del Mar Medical Research Institute (IMIM), Pompeu Fabra University (UPF), 08003 Barcelona, Spain. [Stepniewski TM] Research Programme on Biomedical Informatics (GRIB), Department of Experimental and Health Sciences, Hospital del Mar Medical Research Institute (IMIM), Pompeu Fabra University (UPF), 08003 Barcelona, Spain. InterAx Biotech AG, PARK InnovAARE, 5234 Villigen, Switzerland. [Grau-Expósito J, Perea D, Buzón MJ, Genescà M] Servei de Malalties Infeccioses, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Ayinampudi V] InterAx Biotech AG, PARK InnovAARE, 5234 Villigen, Switzerland |
dc.identifier.pmid | 34948390 |
dc.identifier.wos | 000737887800001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |